A scoping exercise into the current screening and first line treatment of secondary hyperparathyroidism

60 seconds of your time will contribute to the research of tomorrow - thank you!

The following questions relate to a 'grey area' of KDIGO and NICE guidance therefore there are no right or wrong answers. The aim is identify current practice in this area. Please answer honestly based on your current practice.

Question Title

* 1. Is parathyroid hormone (PTH) routinely checked as part of the initial screening process when someone is referred to the nephrology service?

Yes

Comments

Question Title

* 2. At what estimated glomerular filtration rate (eGFR) do you actively monitor someone’s PTH level?

>60ml/min/1.73msq

45-60ml/min/1.73msq

30-44ml/min/1.73msq

15-29ml/min/1.73msq

<15ml/min/1.73msq

Comments

Question Title

* 3. In a patient with stage 4 chronic kidney disease (CKD, eGFR 15-30ml/min/1.73msq), assuming normal serum corrected calcium of 2.25mmol/L and normal serum phosphate of 1.2mmol/L, at what level of PTH would you consider initiating treatment?

1-2 x upper limit of normal

3-4 x upper limit of normal

5-6 x upper limit of normal

7-8 x upper limit of normal

9 or more x upper of limit normal

Comments

Question Title

* 4. In the above scenario what would you use as first line treatment?

Alfacalcidol (1α(OH)D3)

Calcitriol (1,25(OH)2D3)

Cholecalciferol (vitamin D3)

Ergocalciferol (vitamin D2)

Cinacalcet

Other

Comments

Question Title

* 5. Would you/your site be interested in being involved in a non-commercial trial investigating cholecalciferol supplementation in people with non-dialysis dependent CKD?

Yes

If yes, which NHS Trust do you work for?